Abstract
In inflammatory bowel disease (IBD) mucosa, there is over-expression of Smad7, an intracellular inhibitor of the suppressive cytokine transforming growth factor-β1, due to post-transcriptional mechanisms that enhance Smad7 acetylation status thus preventing ubiquitination-mediated proteosomal degradation of the protein. IBD-related inflammation is also marked by defective expression of Sirt1, a class III NAD+-dependent deacetylase, which promotes ubiquitination-mediated proteosomal degradation of various intracellular proteins and triggers anti-inflammatory signals. The aim of our study was to determine whether, in IBD, there is a reciprocal regulation between Smad7 and Sirt1. Smad7 and Sirt1 were examined in mucosal samples of IBD patients and normal controls by Western blotting and immunohistochemistry, and Sirt1 activity was assessed by a fluorimetric assay. To determine whether Smad7 is regulated by Sirt1, normal or IBD lamina propria mononuclear cells (LPMC) were cultured with either Sirt1 inhibitor (Ex527) or activator (Cay10591), respectively. To determine whether Smad7 controls Sirt1 expression, ex vivo organ cultures of IBD mucosal explants were treated with Smad7 sense or antisense oligonucleotide. Moreover, Sirt1 expression was evaluated in LPMC isolated from Smad7-transgenic mice given dextran sulfate sodium (DSS). Upregulation of Smad7 was seen in both the epithelial and lamina propria compartments of IBD patients and this associated with reduced expression and activity of Sirt1. Activation of Sirt1 in IBD LPMC with Cay10591 reduced acetylation and enhanced ubiquitination-driven proteasomal-mediated degradation of Smad7, while inhibition of Sirt1 activation in normal LPMC with Ex527 increased Smad7 expression. Knockdown of Smad7 in IBD mucosal explants enhanced Sirt1 expression, thus suggesting a negative effect of Smad7 on Sirt1 induction. Consistently, mucosal T cells of Smad7-transgenic mice contained reduced levels of Sirt1, a defect that was amplified by induction of DSS colitis. The data suggest the existence of a reciprocal regulatory mechanism between Smad7 and Sirt1, which could contribute to amplify inflammatory signals in the gut.
Highlights
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract with a multifactorial pathophysiology
Total proteins extracted from paired inflammatory bowel disease (IBD) and control samples were analyzed for Smad7 expression by Western blotting and Sirt1 activity by a fluorimetric assay
Values are expressed in arbitrary units (a.u.) and indicate mean ± SEM of all samples. (C) Sirt1 activity was measured in lamina propria mononuclear cells (LPMC) isolated from five inflammatory bowel disease (IBD) patients and cultured in the presence of CAY10591 or dimethyl sulfoxide (DMSO)
Summary
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract with a multifactorial pathophysiology. Accumulating evidence suggests that both Crohn’s disease (CD) and ulcerative colitis (UC), the two major IBD, arise because of the action of multiple environmental and genetic factors, which promote an excessive immune response against component of the luminal flora [1, 2]. In both IBD, there is diminished activity of transforming growth factor (TGF)-β1, an immunosuppressive cytokine that delivers negative signals in many immune cells [3]. Such a defect has been associated with elevated levels of Smad, an intracellular protein that binds to TGF-β receptor type I and inhibits TGF-β1-induced signaling [4, 5]. Inhibition of Smad with a specific antisense oligonucleotide (AS) restores TGF-β1 signaling and reduces inflammatory pathways in both in vitro and in vivo models of intestinal inflammation [5, 6]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.